Actively Recruiting
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Led by Peninsula Health · Updated on 2024-03-20
15
Participants Needed
1
Research Sites
212 weeks
Total Duration
On this page
Sponsors
P
Peninsula Health
Lead Sponsor
M
Monash University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Lung protective ventilation with low tidal volumes and low driving pressure are known to reduce mortality in mechanically ventilated patients with acute respiratory failure. This reduction in mortality is known be due to reduction of ventilator induced lung injury that occurs due to high tidal volumes and high driving pressure. When receiving such mechanical ventilation, some patients develop hypercapnia and associated hypercapnic acidosis. Such patients have an increased risk of mortality. While the exact reasons for such increase in mortality is not known, it is recommended to minimise hypercapnia and hypercapnic acidosis during lung protective ventilation. Minimally invasive extracorporeal carbon dioxide removal (ECCO2R) devices are shown to reduce hypercapnia and hypercapnic acidosis. There are several devices that are currently available in the current clinical practice. However, the effect of these devices on reduction in ventilator induced lung injury is not clearly demonstrated. This study aims to assess the use of an ECCO2R device called Prismalung in reducing ventilator induced lung injury. PrismaLung is currently used in our intensive care unit. This assessment is done by measuring interleukins in bronchoalveolar lavage fluid and blood interleukin levels as well as clinical assessment including the reduction of driving pressure.
CONDITIONS
Official Title
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients (18 years or older) diagnosed with ARDS according to the Berlin Definition
- Driving pressure (ΔP) greater than 14 and/or plateau pressure 25 or higher
- Respiratory rate over 20 breaths per minute
- Blood pH less than 7.25 and PaCO2 greater than 45
You will not qualify if you...
- ARDS lasting more than 72 hours at the time of inclusion
- High plateau pressure over 30 cm H2O or high FiO2 over 0.8 ventilation for more than 7 days
- Life-threatening hemodynamic instability with ongoing arrhythmias not responsive to treatment
- Contraindication to limited anticoagulation
- Treatment limitations such as not for resuscitation or reintubation
- Patients with potentially irreversible respiratory failure caused by conditions like pulmonary fibrosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Frankston Hospital
Frankston, Victoria, Australia, 3199
Actively Recruiting
Research Team
R
RAVINDRANATH TIRUVOIPATI, PhD
CONTACT
S
Sachin Gupta, FCICM
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here